Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ROIV Stock Forecast 2026-2027
$29.08
Current Price
$20.81B
Market Cap
Buy 12
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to ROIV Price Targets
+41.0%
To High Target of $41.00
+20.4%
To Median Target of $35.00
-0.3%
To Low Target of $29.00
ROIV Price Momentum
-0.1%
1 Week Change
+5.0%
1 Month Change
+189.6%
1 Year Change
+34.0%
Year-to-Date Change
-4.1%
From 52W High of $30.33
+190.5%
From 52W Low of $10.01
📊 TOP ANALYST CALLS
Did ROIV Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Roivant is one of their latest high-conviction picks.
Latest ROIV Stock Price Targets & Analyst Predictions
Based on our analysis of 15 Wall Street analysts, ROIV has a bullish consensus with a median price target of $35.00 (ranging from $29.00 to $41.00). The overall analyst rating is Strong Buy (9.4/10). Currently trading at $29.08, the median forecast implies a 20.4% upside. This outlook is supported by 12 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ROIV Analyst Ratings
12
Buy
1
Hold
0
Sell
ROIV Price Target Range
Low
$29.00
Average
$35.00
High
$41.00
Current: $29.08
Latest ROIV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ROIV.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 16, 2026 | Piper Sandler | Yasmeen Rahimi | Overweight | Maintains | $40.00 |
| Mar 4, 2026 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $34.00 |
| Feb 10, 2026 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $33.00 |
| Feb 10, 2026 | Citigroup | Samantha Semenkow | Buy | Maintains | $35.00 |
| Feb 9, 2026 | Guggenheim | Yatin Suneja | Buy | Maintains | $30.00 |
| Dec 15, 2025 | Leerink Partners | David Risinger | Outperform | Maintains | $32.00 |
| Dec 15, 2025 | Goldman Sachs | Corinne Jenkins | Buy | Maintains | $33.00 |
| Dec 12, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $26.00 |
| Nov 11, 2025 | Citigroup | Samantha Semenkow | Buy | Maintains | $26.00 |
| Oct 29, 2025 | Citigroup | Samantha Semenkow | Buy | Maintains | $25.00 |
| Sep 18, 2025 | B of A Securities | Chi Fong | Neutral | Maintains | $16.50 |
| Sep 18, 2025 | Jefferies | Dennis Ding | Buy | Maintains | $20.00 |
| Sep 18, 2025 | Goldman Sachs | Corinne Jenkins | Buy | Maintains | $24.00 |
| Sep 18, 2025 | JP Morgan | Brian Cheng | Overweight | Maintains | $20.00 |
| Sep 18, 2025 | Guggenheim | Yatin Suneja | Buy | Maintains | $21.00 |
| Sep 18, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $20.00 |
| Sep 18, 2025 | Leerink Partners | David Risinger | Outperform | Maintains | $22.00 |
| Sep 2, 2025 | Citigroup | Samantha Semenkow | Buy | Initiates | $16.00 |
| Jun 18, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $18.00 |
| May 28, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $18.00 |
Roivant Sciences Ltd (ROIV) Competitors
The following stocks are similar to Roivant based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Roivant Sciences Ltd (ROIV) Financial Data
Roivant Sciences Ltd has a market capitalization of $20.81B with a P/E ratio of 1.9x. The company generates $13.31M in trailing twelve-month revenue with a 96.9% profit margin.
Revenue growth is -77.8% quarter-over-quarter, while maintaining an operating margin of -16,965.3% and return on equity of -19.1%.
Valuation Metrics
Market Cap
$20.81B
Enterprise Value
$17.63B
P/E Ratio
1.9x
PEG Ratio
0.0x
Price/Sales
1,563.7x
Growth & Margins
Revenue Growth (YoY)
-77.8%
Gross Margin
+65.0%
Operating Margin
-16,965.3%
Net Margin
+96.9%
EPS Growth
-77.8%
Financial Health
Cash/Price Ratio
+21.8%
Current Ratio
30.7x
Debt/Equity
2.2x
ROE
-19.1%
ROA
-14.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Roivant Sciences Ltd (ROIV) Business Model
About Roivant Sciences Ltd
What They Do
Develops transformative medicines and technologies.
Business Model
The company operates by creating specialized subsidiaries, known as Vants, that focus on specific therapeutic areas. Each Vant targets distinct medical conditions, allowing for streamlined drug development and commercialization processes. Roivant generates revenue through the development and potential sale of innovative therapies, as well as partnerships and collaborations in the biopharmaceutical sector.
Additional Information
Founded in 2014 and headquartered in New York City, Roivant has expanded its operations to include technology units that enhance healthcare data sharing and clinical trial processes. The company maintains a diverse pipeline of investigational drugs and is positioned to leverage technological advancements to accelerate the delivery of treatments across various medical fields.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
750
CEO
Mr. Matthew Gline
Country
United Kingdom
IPO Year
2020
Website
roivant.comRoivant Sciences Ltd (ROIV) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Montes Archimedes Acquisition (ROIV) Upgraded to Buy: Here's What You Should Know
Montes Archimedes Acquisition (ROIV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Apr 10, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Montes Archimedes Acquisition (ROIV) has been upgraded to Zacks Rank #2 (Buy), indicating increased optimism about its earnings, which may boost the stock price soon.
Why It Matters
The Zacks Rank #2 upgrade signals increased earnings optimism for Montes Archimedes Acquisition (ROIV), likely boosting investor confidence and potentially driving stock price appreciation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Roivant Sciences Ltd. (ROIV) announced an expansion of its Brepocitinib program and provided an update on Phase III data for Batoclimab.
Why It Matters
Updates on Roivant's drug programs can indicate potential revenue growth and market competitiveness, influencing stock performance and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Brepocitinib is advancing in clinical trials for Lichen planopilaris, addressing a significant unmet need. Immunovant's batoclimab failed in Phase 3 for thyroid eye disease. An investor call is scheduled for April 2, 2026.
Why It Matters
The development of brepocitinib for LPP addresses a significant market need, enhancing its potential value. In contrast, Immunovant's failed TED studies may impact investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)
19 days ago
Quick Summary
Priovant announced a Phase 2b/3 clinical trial for brepocitinib to treat lichen planopilaris (LPP), an inflammatory scalp disorder with no FDA-approved therapies, affecting around 100,000 U.S. adults.
Why It Matters
The development of brepocitinib for LPP addresses a significant unmet medical need, potentially expanding market opportunities and driving investor interest in Priovant's growth and profitability.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Priovant Therapeutics announced the publication of Phase 3 VALOR trial results for brepocitinib in dermatomyositis in NEJM, highlighting its focus on autoimmune disease therapeutics.
Why It Matters
The publication of Phase 3 trial results in a prestigious journal can boost Priovant Therapeutics' credibility, potentially attracting investors and impacting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Roivant Sciences Ltd. (ROIV) Presents at Leerink Global Healthcare Conference 2026 Transcript
1 month ago
Quick Summary
Roivant Sciences Ltd. (ROIV) presented at the Leerink Global Healthcare Conference 2026, highlighting its developments in the healthcare sector.
Why It Matters
Roivant's presentation at a major healthcare conference signals potential developments in its pipeline, influencing investor confidence and stock performance in the biotech sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About ROIV Stock
What is Roivant Sciences Ltd's (ROIV) stock forecast for 2026?
Based on our analysis of 15 Wall Street analysts, Roivant Sciences Ltd (ROIV) has a median price target of $35.00. The highest price target is $41.00 and the lowest is $29.00.
Is ROIV stock a good investment in 2026?
According to current analyst ratings, ROIV has 12 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $29.08. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ROIV stock?
Wall Street analysts predict ROIV stock could reach $35.00 in the next 12 months. This represents a 20.4% increase from the current price of $29.08. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Roivant Sciences Ltd's business model?
The company operates by creating specialized subsidiaries, known as Vants, that focus on specific therapeutic areas. Each Vant targets distinct medical conditions, allowing for streamlined drug development and commercialization processes. Roivant generates revenue through the development and potential sale of innovative therapies, as well as partnerships and collaborations in the biopharmaceutical sector.
What is the highest forecasted price for ROIV Roivant Sciences Ltd?
The highest price target for ROIV is $41.00 from at , which represents a 41.0% increase from the current price of $29.08.
What is the lowest forecasted price for ROIV Roivant Sciences Ltd?
The lowest price target for ROIV is $29.00 from at , which represents a -0.3% decrease from the current price of $29.08.
What is the overall ROIV consensus from analysts for Roivant Sciences Ltd?
The overall analyst consensus for ROIV is bullish. Out of 15 Wall Street analysts, 12 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $35.00.
How accurate are ROIV stock price projections?
Stock price projections, including those for Roivant Sciences Ltd, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 21, 2026 10:14 AM UTC